Abstract

Background Transcatheter Aortic Valve Implantation (TAVI) outnumbers Surgical Aortic Valve Replacement (SAVR) for Aortic Stenosis in the US. Readmission rates and the healthcare burden of these procedures in Solid Organ Transplant (SOT) recipients are poorly studied.

Methods National Readmission Database (2016-2020) was used to identify SOT recipients (Renal, Heart, Kidney, Lung & Pancreas) undergoing TAVI or SAVR. Propensity score matching (PSM) was used to remove confounding factors from outcomes. Descriptive and regression based analysis was performed.

Results Among 3,394 hospitalizations for Aortic Valve Replacement, 2,181 underwent TAVI & 1,213 underwent SAVR. SAVR was associated with higher median LOS (10 vs 2 days) and total cost ($80,842 vs $57,014) in index admission and subsequent readmissions [p<0.001]. From 2016-2020, median LOS (3 to 2 days, p-trend<0.001) and total cost ($61,116 to $54,221, p-trend: 0.002) decreased in the TAVI group but remained the same in the SAVR group (p-value>0.05). Although readmission rates were similar in the two groups, SAVR was associated with higher major adverse cardiovascular events (32.2% vs 19.9%) and net adverse events (82.2% vs 57.2%) at 90-day interval [p<0.001] and subsequently at 180-day interval [p<0.001].

Conclusion In SOT recipients, SAVR is associated with higher median LOS, resource utilization & adverse outcomes on readmission analysis. TAVI has lower resource utilization, and it continues to decrease from 2016-2020.

Document Type

Meeting Abstract

Publication Date

4-2024

Publication Title

Journal of the American College of Cardiology

Last Page

983

Download

Share

COinS